Evidence map›Paper›PMID 40332516›Full record

ArticleInternational journal of molecular sciences2025

Integrating Machine Learning and Follow-Up Variables to Improve Early Detection of Hepatocellular Carcinoma in Tyrosinemia Type 1: A Multicenter Study.

Karen Fuenzalida, María Jesús Leal-Witt, Alejandro Acevedo, Manuel Muñoz, Camila Gudenschwager, Carolina Arias, Juan Francisco Cabello, Giancarlo La Marca, Cristiano Rizzo, Andrea Pietrobattista and 3 more

Abstract readMulticenter Study
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Karen FuenzalidaLaboratory of Genetic and Metabolic Diseases, Institute of Nutrition and Food Technology INTA, University of Chile, Av. El Libano 5524, Santiago 7830490, Chile.ORCID 0000-0001-8829-7336
María Jesús Leal-WittLaboratory of Genetic and Metabolic Diseases, Institute of Nutrition and Food Technology INTA, University of Chile, Av. El Libano 5524, Santiago 7830490, Chile.ORCID 0000-0002-5697-1581
Alejandro AcevedoLaboratory of Genetic and Metabolic Diseases, Institute of Nutrition and Food Technology INTA, University of Chile, Av. El Libano 5524, Santiago 7830490, Chile.
Manuel MuñozLaboratory of Genetic and Metabolic Diseases, Institute of Nutrition and Food Technology INTA, University of Chile, Av. El Libano 5524, Santiago 7830490, Chile.
Camila GudenschwagerLaboratory of Genetic and Metabolic Diseases, Institute of Nutrition and Food Technology INTA, University of Chile, Av. El Libano 5524, Santiago 7830490, Chile.ORCID 0000-0002-4418-8952
Carolina AriasLaboratory of Genetic and Metabolic Diseases, Institute of Nutrition and Food Technology INTA, University of Chile, Av. El Libano 5524, Santiago 7830490, Chile.
Juan Francisco CabelloLaboratory of Genetic and Metabolic Diseases, Institute of Nutrition and Food Technology INTA, University of Chile, Av. El Libano 5524, Santiago 7830490, Chile.
Giancarlo La MarcaMeyer Children's Hospital IRCCS, Viale Gaetano Pieraccini, 24, 50139 Florence, Italy.
Cristiano RizzoDivision of Metabolic Diseases and Hepatology, Ospedale Pediatrico Bambino Gesù IRCCS, 00165 Rome, Italy.
Andrea PietrobattistaDivision of Metabolic Diseases and Hepatology, Ospedale Pediatrico Bambino Gesù IRCCS, 00165 Rome, Italy.ORCID 0000-0002-4426-0395
Marco SpadaDivision of Abdominal Transplantation, Hepato-Bilio-Pancreatic Surgery Unit, Ospedale Pediatrico Bambino Gesù IRCCS, 00165 Rome, Italy.
Carlo Dionisi-ViciDivision of Metabolic Diseases and Hepatology, Ospedale Pediatrico Bambino Gesù IRCCS, 00165 Rome, Italy.ORCID 0000-0002-0007-3379
Verónica CornejoLaboratory of Genetic and Metabolic Diseases, Institute of Nutrition and Food Technology INTA, University of Chile, Av. El Libano 5524, Santiago 7830490, Chile.ORCID 0000-0002-8858-8499

Funding

Agencia Nacional de Investigación y Desarrollo (ANID) FOVI Project 230003
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a major complication of tyrosinemia type 1 (HT-1), an inborn error of metabolism affecting tyrosine catabolism. The risk of HCC is higher in late diagnoses despite treatment. Alpha-fetoprotein (AFP) is widely used to detect liver cancer but has limitations in early-stage HCC detection. This study aimed to implement a machine-learning (ML) approach to identify the most relevant laboratory variables to predict AFP alteration using constrained multidimensional data from Chilean and Italian HT-1 cohorts. A longitudinal retrospective study analyzed 219 records from 35 HT-1 patients, including 8 with HCC and 5 diagnosed through newborn screening. The dataset contained biochemical and demographic variables that were analyzed using the eXtreme Gradient Boosting algorithm, which was trained to predict abnormal AFP levels (>5 ng/mL). Four key variables emerged as significant predictors: alanine transaminase (ALT), alkaline phosphatase, age at diagnosis, and current age. ALT emerged as the most promising indicator of AFP alteration, potentially preceding AFP level changes and improving HCC detection specificity at a cut-off value of 29 UI/L (AUROC = 0.73). Despite limited data from this rare disease, the ML approach successfully analyzed follow-up biomarkers, identifying ALT as an early predictor of AFP elevation and a potential biomarker for HCC progression.

Indexed as

Carcinoma, HepatocellularEarly Detection of CancerLiver NeoplasmsMachine LearningTyrosinemiasAdolescentAdultAlanine TransaminaseAlkaline Phosphatasealpha-FetoproteinsBiomarkers, TumorChildChild, PreschoolFemaleFollow-Up StudiesHumansAlanine TransaminaseAlkaline Phosphatasealpha-FetoproteinsBiomarkers, Tumoralpha-fetoproteinartificial intelligencehepatocellular carcinomahereditary tyrosinemia type 1inborn errors of metabolismliver biomarkers

Identifiers

PMID40332516
PMCPMC12028188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.